Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings

Purpose  Crizotinib has been one of the standard treatment options for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) based on higher progression-free survival (PFS) and objective response rates in phase III clinical trials. However, real-world data a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Akhil, Noronha, Vanita, Patil, Vijay, Menon, Nandini, Nandhana, Ravindra, Kumar, Amit, Mahajan, Abhishek, Janu, Amit, Kumar, Rajiv, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635771/
https://www.ncbi.nlm.nih.gov/pubmed/37969671
http://dx.doi.org/10.1055/s-0042-1753478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635771/
https://www.ncbi.nlm.nih.gov/pubmed/37969671
http://dx.doi.org/10.1055/s-0042-1753478

Ejemplares similares